McKesson is evolving from a low-margin drug distributor into a specialty-and-tech enabled healthcare infrastructure compounder—powered by oncology, Rx access platforms, and aggressive buybacks.
Overview
McKesson is positioned as the foundational “connective tissue” of the North American healthcare supply chain: the largest pharmaceutical distributor by revenue and an increasingly diversified, tech-enabled healthcare services platform. The company has been shifting from a high-volume/low-margin logistics model toward higher-value specialty capabilities—especially oncology—and prescription access technology. FY2026 revenue exceeded $403B, largely from North American Pharmaceutical distribution serving ~50,000 pharmacies and ~3,300 provider locations, supporting ~1.4M patients. Strategically, McKesson sharpened its focus by exiting Europe in early 2026, concentrating on higher-growth North America. Beyond wholesaling, it operates Oncology & Multispecialty services through the U.S. Oncology Network, runs prescription workflow platforms (RxTS) that help patients access complex therapies, and is preparing Medical-Surgical Solutions for separation to unlock value. Customers cite unmatched scale, very high fulfillment accuracy, and deeply integrated software that creates switching costs—positioning McKesson as a secular beneficiary of aging demographics, specialty drug proliferation, and data-driven healthcare delivery.